Peter Powchik, SVP Clinical Development at REGENERON PHARMACEUTICALS INC (REGN), sold 25,000 shares at $55.19 ($1.4M) on 2011-07-26, disclosed to the SEC on 2011-07-26.
Scheduled sale ($1.4M) by SVP Clinical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.26 | 6,949 | $391K | 28.1% |
| 2 | $56.26 | 7,074 | $398K | 28.6% |
| 3 | $54.74 | 7,400 | $405K | 29.1% |
| 4 | $55.19 | 3,577 | $197K | 14.2% |
| Total | $55.66 avg | 25,000 | $1.4M | 100% |
| Filing → |
| REGN | SELL | 2014-01-03 | $5.7M | — | Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |